Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303
https://doi.org/10.1186/s12955-020-01545-3
RESEARCH Open Access
Impact of pre-transplant dialysis modality
on the outcome and health-related quality
of life of patients after simultaneous
pancreas-kidney transplantation
Uwe Scheuermann1 , Sebastian Rademacher1, Nora Jahn2, Elisabeth Sucher3, Daniel Seehofer1,
Robert
Sucher1†
and Hans-Michael
Hau1,4*†
Abstract
Background: Simultaneous pancreas-kidney transplantation (SPKT) profoundly improves thehealth-related quality
oflife (HRQoL)of recipients.However, the influence of the pre-transplant dialysis modality onthe success ofthe
SPKT and post-transplant HRQoL remains unknown.
Methods: Weanalyzedthesurgicaloutcome,long-termsurvival,aswellasHRQoLof83SPKTsthatwereperformedin
ourhospitalbetween2000and2016.Priortotransplant,64patientsreceivedhemodialysis(HD)andnineteenpatients
receivedperitonealdialysis(PD).Physicalandmentalqualityofliferesultsfromeightbasicscalesandthephysicaland
mentalcomponentsummaries(PCSandMCS)weremeasuredusingtheShortForm36(SF-36)survey.
Results:Peri-andpostoperativecomplications,aswellaspatientandgraftsurvivalweresimilarbetweenthetwogroups.
BothgroupsshowedanimprovementofHRQoLinallSF-36domainsaftertransplantation.Comparedwithpatientswho
receivedHDbeforetransplantation,PDpatientsshowedsignificantlybetterresultsinfouroftheeightSF-36domains:
physicalfunctioning(meandifferenceHD-PD:−12.4±4.9,P=<0.01),bodilypain(−14.2±6.3,P<0.01),generalhealth(−
6.3±2.8,P=0.04),vitality(−6.8±2.6,P=0.04),andPCS(−5.2±1.5,P<0.01)afterSPKT.Intheoverallstudypopulation,graft
losswasassociatedwithsignificantworseningoftheHRQoLinallphysicalcomponents(eachP<0.01).
Conclusions:Theresultsofthisanalysisshowthatpre-transplantdialysismodalityhasnoinfluenceontheoutcomeand
survivalrateafterSPKT.RegardingHRQoL,patientsreceivingPDpriortoSPKTseemtohaveaslightadvantagecompared
withpatientswithHDbeforetransplantation.
Keywords:Health-relatedqualityoflife,Hemodialysis,Outcome,Peritonealdialysis,Simultaneouspancreas-kidney
transplantation,Survival
Introduction
Simultaneous pancreas-kidney transplantation (SPKT) offers
*Correspondence:Hans-Michael.hau@uniklinikum-dresden.de
†RobertSucherandHans-MichaelHaubothauthorscontributedequallyto considerable survival benefits for patients with insulin-
thisworkandshareseniorauthorship dependent diabetes mellitus and end-stage renal disease
1DepartmentofVisceral,Transplantation,ThoracicandVascularSurgery, (ESRD), because it restores long-term glycemic control and
UniversityHospitalofLeipzig,Leipzig,Germany canreducesecondarydiabeticcomplications[1–6].
4DepartmentofVisceral,ThoracicandVascularSurgery,UniversityHospital
andFacultyofMedicineCarlGustavCarus,TechnischeUniversitätDresden, Due to organ shortage, most of these patients must
Dresden,Germany undergo long-term renal replacement therapy (RRT)
Fulllistofauthorinformationisavailableattheendofthearticle
©TheAuthor(s).2020OpenAccessThisarticleislicensedunderaCreativeCommonsAttribution4.0InternationalLicense,
whichpermitsuse,sharing,adaptation,distributionandreproductioninanymediumorformat,aslongasyougive
appropriatecredittotheoriginalauthor(s)andthesource,providealinktotheCreativeCommonslicence,andindicateif
changesweremade.Theimagesorotherthirdpartymaterialinthisarticleareincludedinthearticle'sCreativeCommons
licence,unlessindicatedotherwiseinacreditlinetothematerial.Ifmaterialisnotincludedinthearticle'sCreativeCommons
licenceandyourintendeduseisnotpermittedbystatutoryregulationorexceedsthepermitteduse,youwillneedtoobtain
permissiondirectlyfromthecopyrightholder.Toviewacopyofthislicence,visithttp://creativecommons.org/licenses/by/4.0/.
TheCreativeCommonsPublicDomainDedicationwaiver(http://creativecommons.org/publicdomain/zero/1.0/)appliestothe
datamadeavailableinthisarticle,unlessotherwisestatedinacreditlinetothedata.
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page2of9
prior to SPKT. With hemodialysis (HD) and peritoneal variables and complications such as patient, graft as well
dialysis (PD), two efficient RRTs are available pre- as HRQoL outcomes before (during dialysis) and after
transplant. However, both dialysis modalities substantially transplantation. Characteristics included age, gender,
influencepatients’health,aswellastheirabilitytoworkand body mass index (BMI, weight in kg/height in m2), dur-
participate in social activities. Conventional HD is usually ation of insulin-dependent diabetes mellitus, duration of
performed intermittently three times a week in a dialysis dialysis, and time on the waiting list. Cardiovascular dis-
center. During HD, uremic toxins are removed from the ease included information about peripheral arterial ob-
blood extracorporeally through a filter, which is generally structive disease and coronary heart disease (coronary
consideredasastressfulprocedure,withanincreasedriskof artery bypass graft or stent). Peri- and post-transplant
cardiovascular diseases [7, 8]. By contrast, PD uses the peri- data included information on cold ischemia time of the
toneum as a filter through which substances are exchanged kidney/pancreas, immunosuppressive therapy as well as
with the blood. In general, PD offers greater flexibility as it patientandorgangraftfunction.
can be performed at different time points, almost always at Furthermore, complications occurringduringthe first 3
home and independent of medical staff, although it carries monthsaftertransplantationwereanalyzed.Surgicalcom-
the risk of metabolic complications related to systemic glu- plications were defined as the need for relaparotomy
cose absorption from the dialysate (e.g. hyperlipidemia and within the first 3 months after transplantation. Intra-
decompensation of diabetes mellitus), and catheter- abdominal infections were defined as the development of
associated complications. PD catheter infection can lead to infectedfluidcollectionthatrequiredaninterventionand/
subsequent peritonitis, which remains the major cause of orantibioticdrugtherapy.Gastrointestinalbleedingswere
morbidityandmortalityinPDpatients[7,9]. definedasbleedingsrequiringrelaparotomyorendoscopy,
Apart from mere graft and patient survival rates after or patients suffering from sudden anemia combined with
transplantation, measuring the health-Related Quality of either melena or hematemesis. Other bleedings compris-
Life (HRQoL) has become an issue of further interest as ing intra-abdominal hemorrhages, were diagnosed by CT
it provides an overall view of the impact of the disease scanorrelaparotomyperformedduetoacuteanemia.
process on psychosocial status. Monitoring the HRQoL
helpstodefinehowdiseasesymptomsaffectthepatient’s Health-relatedqualityoflife(HRQoL)
life, physical and mental functioning, and their ability to For measuring the HRQoL in this study, the most
copewith thenewlifesituation aftertransplantation. commonly-used and internationally-validated Medical
Recent studies have shown that patients generally ex- Outcomes Study 36-Item Short Form Health Survey
perience better quality of life after SPKT compared with (SF-36) questionnaire was used. Patients were asked to
dialysis patients [4, 10–13]. However, the influence of evaluate their HRQoL before transplantation (undergo-
dialysis modality prior to SPKT on the surgical outcome ing dialysis), such as 1 year after transplantation. There-
and HRQoL after transplantation is less clear. Thus, the fore, SF-36 forms were completed at different time
current study has sought to analyze the outcome and points after transplantation, but not earlier than 1 year
HRQoL in diabetic patients with ESRD undergoing aftertransplantation.
SPKT regarding pre-transplantdialysismodality. HRQoL was evaluated in a second assessment through
written HRQoL questionnaires (SF-36) sent to all pa-
Methods tientswithaninvitationtocompleteaquality-of-life sur-
Studypopulation vey retrospectively. The SF-36 survey was sent by mail
Medical data from patients with insulin-dependent diabetes to patients’ home addresses. Additionally, patients were
mellitus (type 1 or 2) and ESRD who received SPKT at the interviewed via telephone or during a clinical visit, as in-
University Hospital of Leipzig between 2000 and 2016 were dicated. Return envelopes were included free of charge.
retrospectively analyzed. Our data source comprised a pro- A period of 2 weeks was envisaged for returning ques-
spectively collected electronic database. Approval for this tionnaires. All patients who had not returned the ques-
analysis was granted by the local ethics committee [AZ: Nr: tionnaire after 2 weeks were contacted a second time via
111–16-14,032,016]. Patients undergoing pre-emptive trans- mail or telephone within another 14days. Altogether,
plantation, re-transplants, living donor kidney transplant- patients had 4 weeks to submit their responses. Prior to
ation, those aged younger than 18years, and those with the study, informed consent of all patients and the local
missingdatawereexcludedfromthestudy. ethics committee [AZ: Nr: 111–16-14,032,016] was ob-
tained. Because the HRQoL assessment was performed
Outcomemeasures separately,itwasnotpossible tocorrelateHRQoLscores
Special emphasis was placed on the outcome of dialysis with all clinical data. The average time span between
modality before transplantation (HD versus PD), recipi- transplantation and completion of the questionnaires
ent and donor characteristics, intra- and postoperative was8.6±2.9years.
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page3of9
The SF-36 has 36 questions (without specific one for SPKT) as the other. Survival rates were calculated using
renal failure or diabetes) that assess the ability to per- the Kaplan-Meier analysis and the log-rank test was ap-
form vigorous activities and activities for daily living and plied to test statistical significance. Graft survival was
participate in social, family and occupational activities. calculatedasthetimefrom initialtransplanttograft fail-
Eight scales/dimensions describe domains of physical ure (re-start of dialysis), censoring for death with a func-
functions (PF, ten items), role limitations due to physical tioning graft and grafts still functioning at time of
problems (PR, four items), bodily pain (BP, two items), a analysis. Patient survival is defined as time from trans-
generalperception ofhealth (GH,five items), energyand plant to patient death, censoring for patients still alive at
vitality (VIT, four items), social functions (SF, two time of analysis. If a recipient was alive or lost to follow-
items), role limitations due to emotional problems (RE, up at time of last contact, then survival time was cen-
three items), and mental health (MH, five items). The sored at time of last contact. Multivariate Cox propor-
subscales can be combined into two summation scales tionalhazardsanalysis wasapplied toassessindependent
measuring the overall physical and mental HRQoL: a predictors of patient death and pancreas graft failure, in-
physical component summary (PCS=PF+PR+BP+ cluding clinically-relevant variables and/or those pre-
GH) and a mental component summary (MCS=VIT+ senting P≤0.15 in univariate analysis: recipient gender,
SF+RE+MH). Subscale scores were transformed to a BMI and age, dialysis modality (HD versus PD), time on
0–100 scale, with 0 representing the least to 100 repre- dialysis, years of diabetes mellitus, concomitant cardio-
sentingthegreatestwell-being. vascular disease and surgical complications. SPSS soft-
ware (SPSS Inc., Chicago, Illinois, USA, version 21.0)
Surgicaltechniques was used for statistical analysis and graphs. A P value <
The pancreas and kidney grafts were procured according 0.05wasconsidered asstatistically significant.
totheguidelinesprovidedbyEurotransplant(ET)[14].As
described earlier, the pancreas was explanted in a no- Results
touchtechnique[15].Anilliacy-graftwasusedforrecon- Baselinecharacteristics
struction of the superior mesenteric and the lienal artery. Theoverallstudypopulationincluded83patientsreceiv-
The pancreas was transplanted transabdominally using a ing SPKT in our department between 2000 and 2016. At
standardtechniquewithanintraperitoneallocationinthe thetimeoftransplantation,64patientsobtained HDand
right iliac fossa [16]. Exocrine drainage was carried out nineteen patients used PD. Continuous ambulatory peri-
with a side-to-side duodenojejunostomy [3, 17]. Kidneys toneal dialysis was used by fourteen patients (74%) and
were transplanted transabdominally into the left iliacal automatic peritoneal dialysis was used by five patients
fossa. The ureter was implanted into the bladder accord- (26%) among the PD group. Recipient, donor and graft
ing to the Lich-Gregoir technique using a double J intra- characteristics according to the different dialysis types
ureteralsplint[16]. prior to transplantation are summarized in Table 1. The
two groups were similar for the majority of their pre-
Immunosuppression transplant characteristics, while the number of female
Immunosuppressive therapy comprised an induction recipients was higher in the PD group (P=0.017), and a
therapy with the interleukin-2 receptor antagonist basi- history of depression was more frequent in the HD
liximab or antithymocyte globulin, followed by a triple group (P=0.049). HLA mismatches, post-transplant im-
maintenance immunosuppression consisting of calcine- munosuppressive regimes and lengths of hospital stay
urin inhibitors (tacrolimus or cyclosporine), and/or anti- did not show significant differences between the two
metabolites (mycofenolate mofetil or sirolimus) and groups(datanot shown).
taperedsteroids(prednisolone).
Outcome
Statisticalanalysis Complications
Baseline data are presented as mean values with the There were no significant differences in the frequency of
standard deviation (SD), minimum or maximum range peri- and postoperative complications between HD and
such as the proportion percentage (%). Baseline data PD SPKT recipients (Table 2). The global relaparotomy
were compared with appropriate statistical significance rate was similar between the two groups (HD: 35% ver-
test including the Student’s t–test, χ2, analysis of vari- susPD: 36%;P=0.77).
ance (ANOVA), Kruskal-Wallis and Wilcoxon–Mann– After transplantation, eighteen patients developed
Whitney tests. Analysis of covariance (ANCOVA) was intra-abdominal infections (HD: 20% versus PD: 26%;
used to adjust the difference between the two groups P =0.577). There were eight bacterial infections, two
after SPKT, with hemodialysis as one predictor and fungal infections and eight cultured positive for both
baseline measurements of HRQoL domains (before bacteria and fungi. Intra-abdominal infections were
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page4of9
Table1Demographicandclinicopathologiccharacteristicsof Table2Post-transplantcomplicationsandcausesof
thestudycohortpriortotransplantation.Dataareshownas relaparotomy.CMV,cytomegalovirus;GI,gastrointestinal;HD,
mean±SD.ALT,antilymphocyteglobulin;ATG,anti-thymocyte hemodialysis;PD,peritonealdialysis;SPKT,simultaneous
globulin;BMI,bodymassindex;CMV,cytomegalovirus;D+, pancreas-kidneytransplantation
donorpositive;R+recipientpositive;HbA1c,glycated Variables HD(N=64) PD(N=19) P-value
hemoglobin;HD,hemodialysis;IL-2RA,Interleukin-2receptor
Acutecombinedgraftrejection 12(19%) 3(16%) 0.769
antagonist;PD,peritonealdialysis;SPKT,simultaneouspancreas-
kidneytransplantation Delayedgraftfunctionkidney 10(16%) 2(11%) 0.80
Variables HD(N=64) PD(N=19) P-value Anastomoticleak 2(3%) 1(5%) 0.66
Recipient Graftthrombosis 7(11%) 4(21%) 0.254
Age,years 43.8±9.1 43.2±9.7 0.845 GI-bleeding 7(11%) 1(5%) 0.426
Gender Othermajorbleeding 9(14%) 2(11%) 0.69
Male 40(62.5%) 6(31.6%) 0.017 Intra-abdominalinfection 13(20%) 5(26%) 0.577
Female 24(37.5%) 13(68.4%) Graftpancreatitis 11(17%) 3(16%) 0.88
BMI,kg/m2 25.8±4.4 24±3.6 0.105 CMVinfection 21(33.3%) 5(26.3%) 0.564
Durationdiabetesmellitus,years 27.1±8.4 26.1±8.6 0.685 Woundinfections 9(14%) 3(16%) 0.851
Timeondialysis,months 30.5±21.3 27.0±22.1 0.536 Re-operation/relaparotomy 23(35%) 7(36%) 0.77
HbA1cpre-transplantation,% 7.7±1.8 7.7±1.2 0.940 Causesrelaparotomy
Timeonwaitinglist,months 10.9±13.6 7.2±6.9 0.242 Infection 8(13%) 2(11%) 0.76
Comorbidities Bleeding 6(9%) 1(5%) 0.51
Diabeticretinopathy 56(87.5%) 13(68.4%) 0.050 Thrombosis 7(11%) 3(16%) 0.54
Diabeticneuropathy 39(60.9%) 11(57.9%) 0.812 Others 2(3%) 1(5%) 0.66
Arterialobstructivedisease 12(18.8%) 2(10.5%) 0.401
Coronaryheartdisease 21(32.8%) 2(10.5%) 0.050 of peritonitis was not associated with an increased risk
Depression 21(32.8%) 2(10.5%) 0.049 of complications after transplantation, whereby only one
of these patients had an intra-abdominal infection and
Takingaspirinpre-SPKT 23(35.9%) 9(47.4%) 0.367
onepatientdeveloped pancreatitispost-transplant.
Donor
Age,years 24.1±11.8 19.2±7.8 0.109
Patientandgraftsurvival
Gender The 3- and 5-year patient survival rates for patients after
Male 37(57.8%) 14(73.3%) 0.212 SPKT showed no significant differences between the HD
Female 27(42.2%) 5(26.3%) and PD group (98.2 and 96.1% in HD versus 92.9 and
BMI,kg/m2 22.4±3.1 22.1±2.8 0.987 92.9% in PD, respectively; P=0.559). Similarly, the 1-, 3-
and 5- year pancreas graft survival rates (94.6, 90.3 and
Graft
85.8% in HD versus 88.2, 81.9 and 81.9% in PD, respect-
Kidneycoldischemia,hours 11.0±3.3 11.1±2.6 0.978 ively; P=0.901) and kidney graft survival rates (98.2,
Pancreascoldischemia,hours 10.1±1.9 10.9±3.9 0.294 96.4 and84.3% inHDversus 88.2,88.2 and 80.2%inPD,
CMVstatus respectively; P=0.712) did not show any significant dif-
CMVD+ 31(48.4%) 11(64.7%) 0.211 ferencesbetweenthetwo groups(Fig.1).
AsshowninTable3,nosignificantdifferenceswerefound
CMVR+ 36(56.3%) 13(68.4%) 0.343
between the type of pre-transplant dialysis modality and
InductionTherapy
causesforpatientdeathandgraftfailure.However,wenoted
ALG/ATG 54(84.4%) 15(78.9%) 0.864
atendencyofhighergraftlossesduetothrombosisinPDpa-
IL2-RA 7(10.9%) 3(15.8%) 0.568 tients(HD:4.7%versusPD:15.8%;P=0.10).
None 3(4.7%) 1(5.3%) 0.916 Multivariate Cox regression analysis of the total study
population revealed that the presence of cardiovascular
complicated with graft pancreatitis in nine cases (HD: disease is an independent predictor of patient death.
10% versus PD: 11%; P=0.89) and relaparotomy was ne- Moreover, the preoperative presence of cardiovascular
cessary in ten cases (HD: 13% versus PD: 11%; P =0.76). disease, recipient age, BMI, duration of pre-transplant
Four out of nineteen PD patients had a history of peri- dialysis and surgical complications could be identified as
tonitis during their time on dialysis, including two pa- independent predictors of pancreas and kidney graft loss
tients with two or more episodes ofperitonitis. A history (Table4).
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page5of9
Fig.1(a)Patient,(b)pancreasgraftand(c)kidneygraftsurvivalafterSPKTaccordingtodialysismodality.HD,hemodialysis;PD,peritonealdialysis
Health-relatedqualityoflife(HRQoL)
Impact of pre-transplant dialysis modality Tables 5
compares the HRQoL scores of SPKT recipients accord-
Table4MultivariateCoxregressionanalysisofpredictorsof
ing to their dialysis modality before and after transplant-
patientdeathandpancreasgraftloss.BMI,bodymassindex;
ation. Both groups showed an improvement of HRQoL
HD,hemodialysis;HR(95CI),hazardratio(95%confidence
in all SF-36 domains after transplantation. There were interval);PD,peritonealdialysis
statistically significant improvements in six of the eight
Variables HR(95CI) P-value
SF-36 domains in the HD group, and in seven of the
Patientdeath
eightSF-36 domainsinthePDgroup.
Cardiovasculardisease 6.12(1.7–21.19 0.005
Before transplantation, benefits were seen for the PD
patients, with statistically significant differences in terms Dialysismodality(PDvsHD) 1.72(0.37–7.71) 0.70
of physical functioning (P=0.028), bodily pain (P= Recipientage 0.96(0.90–1.04) 0.33
0.034), and in the physical component summary (PCS) Recipientgender(malevsfemale) 1.36(0.41–4.44) 0.60
Monthsondialysis 1.01(0.9–1.0) 0.25
Table3Causesofpatientdeathandpancreasandkidneygraft
lossaftersimultaneouspancreas-kidneytransplantation Yearsofdiabetes 1.01(0.9–1.2) 0.65
Variables HD(N=64) PD(N=19) P-value RecipientBMI 1.02(0.88–1.18) 0.75
Patientdeath Pancreasgraftfailure
Total 12(19%) 3(16%) 0.78 Cardiovasculardisease 3.36(1.14–9.89) 0.02
Cardiovascular 6(9.4%) 2(10.5%) 0.88 Dialysismodality(PDvsHD) 1.35(0.43–4.27) 0.60
Infection 4(6.3%) 1(5.3%) 0.87 Recipientage 1.2(0.99–1.12) 0.01
Other 2(3.1%) 0(0%) 0.43 Recipientgender(malevsfemale) 2.01(0.81–4.92) 0.129
Pancreasgraftfailure Monthsondialysis 0.98(0.96–1.10) 0.001
Total 15(23%) 5(26%) 0.79 Yearsofdiabetes 1.02(0.94–1.06) 0.95
Rejection 3(4.7%) 0(0%) 0.33 Surgicalcomplications 6.48(2.66–15.74) 0.001
Thrombosis 3(4.7%) 3(15.8%) 0.10 RecipientBMI 1.2(1.08–1.35) 0.01
Bleeding 2(3.1%) 0(0%) 0.43 Kidneygraftfailure
Infection 5(7.8%) 2(10.5%) 0.70 Cardiovasculardisease 2.53(0.82–7.46) 0.019
Other 2(3.1%) 0(0%) 0.43 Dialysismodality(PDvsHD) 1.01(0.28–3.59) 0.986
Kidneygraftfailure Recipientage 1.2(0.99–1.12) 0.01
Total 13(20%) 3(16%) 0.19 Recipientgender(malevsfemale) 2.1(0.75–6.1) 0.15
Rejection 6(9%) 1(5%) 0.32 Monthsondialysis 0.96(0.93–1.2) 0.001
Thrombosis 2(3%) 1(5%) 0.66 Yearsofdiabetes 1.1(0.95–1.08) 0.74
Infection 3(5%) 1(5%) 0.91 Surgicalcomplications 3.4(1.5–6.9) 0.03
Other 2(3%) 0(0%) 0.45 RecipientBMI 1.19(1.06–1.33) 0.003
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page6of9
Table5ComparisonofHRQoLbetweenHDandPDpatientsbeforeandafterSPKT.Dataareshownasmean±SD.HD,
hemodialysis;MCS,mentalcomponentsummary;MD,meandifference;PCS,physicalcomponentsummary;PD,Peritonealdialysis;
SF-36,ShortForm36;SPKT,simultaneouspancreas-kidneytransplantation
Groups HD-PD
SF-36dimensions HD(N=64) PD(N=19) BeforeSPKT AfterSPKT
BeforeSPKT AfterSPKT P-value BeforeSPKT AfterSPKT P-value MD P-value MD P-value
Physcialfunctioning 48.3±13.3 68.9±8.9 <0.01 63.8±17.7 81.3±15.9 0.030 −15.2±7.1 0.028 −12.4±4.9 <0.01
Rolelimitations-physical 38.3±31.3 60.7±25.4 0.040 56.2±43.8 72.9±19.8 <0.01 −17.9±16.4 0.267 −12.2±9.1 0.49
BodilyPain 44.2±21.2 71.1±8.5 <0.01 64.1±17.6 85.3±9.8 <0.01 −19.9±9.3 0.034 −14.2±6.3 <0.01
Generalhealth 36.5±16.1 61.6±7.5 <0.01 48.8±7.0 67.9±6.8 <0.01 −12.3±6.3 0.053 −6.3±2.8 0.04
Socialfunction 55.8±17.6 65.2±12.2 0.110 68.8±11.6 73.9±11.2 0.329 −13.0±7.4 0.077 −8.7±4.6 0.15
Vitality 42.7±11.2 61.1±7.4 <0.01 48.8±18.5 67.9±5.4 <0.01 −6.1±6.6 0.333 −6.8±2.6 0.04
Rolelimitations-emotional 44.4±29.9 61.9±28.8 0.122 66.7±30.9 83.3±22.5 0.178 −22.3±12.9 0.109 −21.4±10.3 0.36
MentalHealth 51.4±16.4 63.4±5.8 0.010 49.5±2.8 62.3±8.2 <0.01 −1.9±4.9 0.681 −1.1±2.7 0.96
PCS 34.9±5.8 45.6±4.6 <0.01 43.1±8.6 50.8±2.5 <0.01 −8.2±3.1 0.013 −5.2±1.5 <0.01
MCS 40.2±6.6 44.7±4.5 0.042 41.6±5.4 46.8±3.8 0.021 −1.4±2.9 0.624 −2.1±1.6 0.32
(P=0.013) compared with patients receiving HD prior between HD and PD patients after SPKT [21–24]. Our
to transplantation (Table 5). After SPKT, PD patients analysis could not reveal significant differences in intra-
showed significantly better results in four of the eight abdominal infection rates after SPKT between the two
SF-36 domains compared with HD patients: physical groups, and there was no correlation between the inci-
functioning (P<0.01), bodily pain (P<0.01), general dence of pre-transplant peritonitis and post-transplant
health (P=0.04),vitality (P=0.04)andPCS(P<0.01). intra-abdominal infection. Besides dialysis modality, the
incidence of intra-abdominal infection after SPKT may
Impact of demographical and clinical variables We be related to other factors, namely surgical technique
separately analyzed the possible impact of three factors (especially pancreas-anastomosis), the length of hospital
– age, gender and graft loss – on the HRQoL of the staysandthe intensityofimmunosuppression.
overall study population after SPKT (Table 6). Regarding In the literature, there are reports of an increased graft
patients’ age, there was a significant difference in phys- loss in PD patients compared with HD patients post-
ical functioning (P=0.04), general health (P <0.01) and transplant. After KTA, an increased graft loss in PD pa-
role limitations (P =0.03). In the univariate analysis, pa- tients is reported, mainly due to renal vascular throm-
tients’ gender showed no influence on HRQoL after bosis [25, 26]. In a study investigating outcomes after
SPKT. Graft loss (kidney or pancreas) led to asignificant SPKT, Martins et al. reported a significantly higher rate
decrease in all physical components (each P<0.01) and of thrombosis-driven relaparotomy in PD patients com-
mental healthstatus(P=0.01) ofthe SF-36. pared with HD patients. Moreover, they recognized a
near significant higher rate of renal graft loss due to
Discussion thrombosis in PD patients compared with HD patients
Post-transplantoutcomeandsurvival [20]. In our study, no correlations were found between
Infectious complications remain a significant cause of pre-transplant dialysis modality and patient or graft sur-
morbidity and mortality after SPKT [3, 4, 6, 18]. A vival. Only the rate of pancreas graft failure due to
much-debated question is whether pre-transplant PD in- thrombosis was non-significantly higher in the PD group
creases the risk for intra-abdominal infections after (HD: 4.7% versus PD: 15.8%, P=0.10). However, these
transplantation due to the risk of catheter-associated data must be interpreted with caution, because other
peritonitis. Binaut et al. showed a higher rate of parietal variables such as patient comorbidities (cardiovascular
sepsis in PD patients after kidney transplantation alone diseases, BMI), along with recipient age and time ondia-
(KTA) compared with patients who received HD prior lysis might be additional factors that influence the out-
to transplantation [19]. Martins et al. reported a signifi- comeandsurvival.
cantly higher rate of pancreas loss due to infection
among PD patients after SPKT (HD: 3.4% versus PD: Health-relatedqualityoflife(HRQoL)
12.8%; P=0.042), whereas ten out of 39 (25.6%) PD pa- Pre-transplantHRQoL
tientshadperitonitisintheirpast[20].Bycontrast,other Most published studies evaluating dialysis patients wait-
studies have reported no difference in surgical outcome ing for KTA show inconclusive results related to pre-
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page7of9
Table6Univariateanalysis:impactofclinicalanddemographicalvariablesonSF-36resultsofallpatientsaftertransplantation(n=
83).Dataareshownasmean±SD
SF-36dimensions Age Gender Graftloss
<45years >45years P-value Male Female P-value No Yes P-value
Physcialfunctioning 80.1±11.2 69.8±14.3 0.04 77.8±13.4 74.2±14.3 0.499 86.8±6.8 65.6±10.3 <0.01
Rolelimitations-physical 73.5±20.6 61.1±13.1 0.09 69.3±17.6 67.6±20.1 0.308 76.3±15.1 45.8±10.2 <0.01
BodilyPain 80.1±11.7 72.2.±9.6 0.1 79.8±12.3 76.1±11.1 0.416 81.8±8.9 67.9±7.7 <0.01
Generalhealth 67.9±5.8 59.8±7.6 <0.01 63.1±9.1 66.4±5.2 0.276 82.8±8.5 46.7±5.8 <0.01
Socialfunction 72.1±10.4 63.9±14.6 0.11 68.2±15.6 70.0±10.4 0.719 73.9±11.2 65.0±12.1 0.08
Vitality 66.2±5.7 61.8±9.2 0.15 67.3±7.2 61.3±6.7 0.047 66.4±5.9 55.2±5.1 0.06
Rolelimitations-emotional 82.1±22.4 61.5±23.7 0.03 68.9±29.4 75.8±21.6 0.545 80.1±5.1 61.1±20.3 0.09
MentalHealth 63.3±7.9 62.4±5.6 0.66 63.7±7.5 61.8±6.3 0.498 65.1±5.6 57.1±1.3 0.01
transplant HRQoL and dialysis modality [27]. Previous The authors showed that pre-existing psychiatric disor-
publications have used a broad range of measures to as- ders at the time of transplant were the only significant
sess HRQoL and analyzed patients with different demo- predictor of reduced quality of life following pancreas
graphic characteristics and medical history. Ourfindings transplantation [33]. In line with these reports, in our
indicate that PD is associated with a significantly better study the rate of depression in patient history was sig-
physical functioning and physical component summary nificantly higher in the HD group (P=0.049). However,
before SPKT compared with patients receiving HD as a with a small sample size and missing details about psy-
pre-transplantdialysismodality.Moreover,besidesmental chosocial status and longitudinal periodic assessment of
health, all other components of the SF-36 score were (al- depression disease, caution must be applied as the find-
thoughnotsignificantly)higherinPDpatients.Thebetter ingsmightnot berepresentative.
reportedqualityoflifeamongPDpatientsmaystemfrom In the literature, the relative importance of patients’
the positive effect of medical self-management through gender on HRQoL after transplantation is debated. In a
PD, which can be performed independently or with the studybyRajkumaretal.,12monthsaftertransplantation
help of a caregiver and develops a sense of personal con- (KTA or SPKT) most HRQoL scores (seven out of eight)
trol, which positively correlates with features of HRQoL. were better for women than for men. Moreover, HRQoL
By contrast, conventional HD is a stressful process and scores of female recipients were not statistically different
time spent on a dialysis ward can contribute to a lower from the control group in the general population [12].
qualityoflife,asthenumberofhoursinHDhinderspro- The authors postulated that differences in expectations
fessionalandsocialfunctioning. and appreciation of improvements in health after trans-
plantation, differences in social network and emotional
Post-transplantHRQoL support may provide an explanation for these findings.
The HRQoL of patients improved in both study groups Other reports have favored men and shown that female
after transplantation, which underlines the therapeutic gender is a negative predictive factor of HRQoL after
success of SPKT, besides medical outcomes and object- SPKT [10, 33]. In a study by Martin et al. evaluating
ive clinical parameters. This is in line with most pub- HRQoL in 60 male and 66 female SPKT patients, no
lished studies showing a significant improvement in lower scores for female patients were observed [11]. Dif-
patient-reported general HRQoL after SPKT and better ferent results in the literature may be explained by dif-
diabetes-specificquality oflife[4,10–13]. ferent follow-up periods, study populations and study
Psychiatric disorders could influence the poor evalu- designs/questionnaires. In our analysis, the number of
ation of the quality of life among HD patients [28]. HD female recipients was significantly higher in the PD
carries the risk of vascular dehydration and hypotension group (P=0.017), although we did not observe gender-
following cerebellar hypoperfusion and may lead to cog- based differencesintheoverallstudy population.
nitive impairment and cardiovascular diseases [29–31]. Inthepresentstudy,wehaveshownthatgraftlosshasa
Sapilak revealed a strong negative correlation of HRQoL significant impact on HRQoL after SPKT due to a loss of
of HD patients with depression symptoms and anxiety independencefrominsulintherapyandfreedomfromdia-
[32]. In a study by Smith et al. evaluating 37 patients lysis. This is in line with previous publications in which
pre-transplant and 4 months after SPKT, approximately graft loss has been associated with significant worsening
half of the patients showed an improvement of HRQoL, of the HRQoL [4, 34, 35], and maintenance of two func-
although one-third even experienced reduced HRQoL. tioning grafts seems to be an independent predictor of
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page8of9
higher post-transplant quality-of-life scores [11]. Further- identificationofthesepatients.Therefore,accordingtoorganizational
more, the results of Sutherland et al. indicate that achiev- restrictionsandregulationsthesedatacannotbemadepublicallyavailable.
However,thedatasetsusedand/oranalyzedduringthecurrentstudyare
ing insulin independence improves QOL more than
availablefromthecorrespondingauthoronreasonablerequest.
becomingdialysis-free[4].
Ethicsapprovalandconsenttoparticipate
Limitations Thestudywasapprovedbythelocalethicalcommissionboardfromthe
UniversityofLeipzig(AZEK:111–16-14032016).Priortothestudy,the
There are some notable limitations of this study that
patientswereinformedofthepurposeoftheresearch.Participantswere
should be mentioned, related to the data source and assuredoftheirrightofrefusaltoparticipateortowithdrawfromthestudy
study design. The main limitations of the study are its atanystage.Theparticipants’nameswereremovedfromthedata.
retrospective nature, the heterogenous group size and
Consentforpublication
the fact that all data collection was undertaken at one
Notapplicable.
time, which make it difficult to evaluate the causality of
the findings and associations. As such, there may be
Competinginterests
some amount of variation from year to year with Theauthorsdeclarethattheyhavenocompetinginterests.
changes in the outcome and level of HRQoL. Second,
Authordetails
not only disease or dialysis modality determine one’s 1DepartmentofVisceral,Transplantation,ThoracicandVascularSurgery,
view of life quality, but also many non-disease factors UniversityHospitalofLeipzig,Leipzig,Germany.2Departmentof
(work, education, and other sociodemographic factors) AnesthesiologyandIntensiveCareMedicine,UniversityHospitalofLeipzig,
Leipzig,Germany.3DepartmentofGastroenterology,UniversityHospitalof
play important additive role in the perception of Leipzig,Leipzig,Germany.4DepartmentofVisceral,ThoracicandVascular
HRQoL. The option for PD or HD normally depends on Surgery,UniversityHospitalandFacultyofMedicineCarlGustavCarus,
the patient’s condition (comorbid situations, vascular TechnischeUniversitätDresden,Dresden,Germany.
and peritoneal conditions), autonomy and convenience,
Received:19January2020Accepted:26August2020
aswell asthehealthcaresystem (dialysis center factors).
Conclusions References
1. DeanPG,KudvaYC,StegallMD.Long-termbenefitsofpancreas
Both dialysis modalities are generally associated with transplantation.CurrOpinOrganTransplant.2008;13(1):85–90.https://doi.
good outcomes and an improvement of HRQoL after org/10.1097/MOT.0b013e3282f2fd7fReview.PubMedPMID:18660712.
SPKT. PD prior to SPKT seems to offer a slight advan- 2. MohanP,SafiK,LittleDM,DonohoeJ,ConlonP,WalsheJJ,O'KellyP,
ThompsonCJ,HickeyDP.Improvedpatientsurvivalinrecipientsof
tage compared with HD before transplantation. Further
simultaneouspancreas-kidneytransplantcomparedwithkidneytransplant
prospective, controlled and randomized studies are aloneinpatientswithtype1diabetesmellitusandend-stagerenaldisease.
needed to evaluate sociodemographic factors with an
BrJSurg.2003;90(9):1137–41PubMedPMID:12945083.
3. SollingerHW,OdoricoJS,BeckerYT,D’AlessandroAM,PirschJD.One
impactontheoutcomeandHRQoL.
thousandsimultaneouspancreas-kidneytransplantsatasinglecenterwith
22-yearfollow-up.AnnSurg.2009;250:618–30.
Abbreviations 4. SutherlandDE,GruessnerRW,DunnDL,MatasAJ,HumarA,KandaswamyR,
BMI:Bodymassindex;ESRD:Endstagerenaldisease;HD:Hemodialysis; MauerSM,KennedyWR,GoetzFC,RobertsonRP,GruessnerAC,NajarianJS.
HRQoL:Health-relatedqualityoflife;KTA:Kidneytransplantationalone; Lessonslearnedfrommorethan1,000pancreastransplantsatasingle
MMF:Mycophenolatemofetil;PD:Peritonealdialysis;RRT:Renalreplacement institution.AnnSurg.2001;233(4):463–501Review.PubMedPMID:11303130;
therapy;SD:Standarddeviation;SF-36:ShortForm36;SPKT:Simultaneous PubMedCentralPMCID:PMC1421277.
pancreas-kidneytransplantation 5. VanDellenD,WorthingtonJ,Mitu-PretorianOM,GhazanfarA,ForgacsB,
PararajasingamR,CampbellB,ParrottNR,AugustineT,TavakoliA.Mortality
Acknowledgements indiabetes:pancreastransplantationisassociatedwithsignificantsurvival
WeacknowledgesupportfromtheGermanResearchFoundation(DFG)and benefit.NephrolDialTransplant.2013;28(5):1315–22.https://doi.org/10.1093/
UniversityofLeipzigwithintheprogramofOpenAccessPublishing. ndt/gfs613Epub2013Mar19.PubMedPMID:23512107.
6. WhiteSA,ShawJA,SutherlandDE.Pancreastransplantation.Lancet.2009;
Authors’contributions 373(9677):1808–17.https://doi.org/10.1016/S0140-6736(09)60609-7Review.
HMHandRSwereresponsibleforthestudyconceptionanddesign;HMH, PubMedPMID:19465236.
NJ,SR,ESandRSwereresponsiblefordataacquisition;US,HMH,SR,andRS 7. FischerA.Hemo-andperitonealdialysis:whatnon-nephrologistsshould
analyzedandinterpretedthedata;US,HMH,SRandRSdraftedthe know.TherUmsch.2018;75(6):387–94.https://doi.org/10.1024/0040-5930/
manuscript;andNJ,ES,andDScriticallyrevisedthemanuscript.Allauthors a001013Review.German.PubMedPMID:30880624.
readandapprovedthefinalmanuscript. 8. CozzolinoM,ManganoM,StucchiA,CiceriP,ConteF,GalassiA.
Cardiovasculardiseaseindialysispatients.NephrolDialTransplant.2018;
Funding 33(suppl_3):iii28–34.https://doi.org/10.1093/ndt/gfy174Review.PubMed
ThisworkwassupportedbytheGermanResearchFoundation(DFG)and PMID:30281132;PubMedCentralPMCID:PMC6168816.
LeipzigUniversitywithintheprogramofOpenAccessPublishing.The 9. MehrotraR,DevuystO,DaviesSJ,JohnsonDW.Thecurrentstateof
fundershadnoroleinstudydesign,datacollectionandanalysis,decisionto peritonealDialysis.JAmSocNephrol.2016;27(11):3238–52Epub2016Jun
publish,orpreparationofthemanuscript.OpenAccessfundingprovidedby 23.Review.PubMedPMID:27339663;PubMedCentralPMCID:PMC5084899.
ProjektDEAL. 10. IslaPeraP,MonchoVasalloJ,TorrasRabasaA,OppenheimerSalinasF.
FernándezCruzPérezL,RicartBrullesMJ.Qualityoflifeinsimultaneous
Availabilityofdataandmaterials pancreas-kidneytransplantrecipients.ClinTranspl.2009;23(5):600–5.https://
Ourdatabasecontainshighlysensibledatawhichmayprovideinsightin doi.org/10.1111/j.1399-0012.2009.01054.xEpub2009Aug11.PubMedPMID:
clinicalandpersonnelinformationaboutourpatientsandleadto 19674015.
Scheuermannetal.HealthandQualityofLifeOutcomes (2020) 18:303 Page9of9
11. MartinsLS,OutereloC,MalheiroJ,FonsecaIM,HenriquesAC,DiasLS, 29. Polinder-BosHA,GarcíaDV,KuipersJ,EltingJWJ,AriesMJH,KrijnenWP,
RodriguesAS,CabritaAM,NoronhaIL.Health-relatedqualityoflifemay GroenH,WillemsenATM,vanLaarPJ,StrijkertF,LuurtsemaG,SlartRHJA,
improveaftertransplantationinpancreas-kidneyrecipients.ClinTranspl. WesterhuisR,GansevoortRT,GaillardCAJM,FranssenCFM.Hemodialysis
2015;29(3):242–51.https://doi.org/10.1111/ctr.12511Epub2015Jan30. InducesanAcuteDeclineinCerebralBloodFlowinElderlyPatients.JAm
PubMedPMID:25581297. SocNephrol.2018;29(4):1317–25.https://doi.org/10.1681/ASN.2017101088
12. RajkumarT,MazidS,Vucak-DzumhurM,SykesTM,ElderGJ.Health-related Epub2018Mar1.Erratumin:JAmSocNephrol.2018Aug;29(8):2256.
qualityoflifefollowingkidneyandsimultaneouspancreaskidney PubMedPMID:29496888;PubMedCentralPMCID:PMC5875962.
transplantation.Nephrology(Carlton)2019Sep;24(9):975–982.doi:https:// 30. MurrayAM,TupperDE,KnopmanDS,GilbertsonDT,PedersonSL,LiS,
doi.org/10.1111/nep.13523.Epub2019Apr29.PubMedPMID:30393905. SmithGE,HochhalterAK,CollinsAJ,KaneRL.Cognitiveimpairmentin
13. SureshkumarKK,PatelBM,MarkatosA,NghiemDD,MarcusRJ.Qualityof hemodialysispatientsiscommon.Neurology.2006;67(2):216–23Erratumin:
lifeafterorgantransplantationintype1diabeticswithend-stagerenal Neurology.2007Jul3;69(1):120.PubMedPMID:16864811.
disease.ClinTranspl.2006;20(1):19–25PubMedPMID:16556148. 31. VanBiesenW,VanholderRC,VeysN,DhondtA,LameireNH.Anevaluation
14. Eurotransplant.Chapter9:TheDonor.https://eurotransplant.org/cms/mediaobject. ofanintegrativecareapproachforend-stagerenaldiseasepatients.JAm
php?file=H9+The+Donor_August+20161.pdf.Accessed19Jan2020. SocNephrol.2000;11(1):116–25.10616847.
15. LadurnerR,SteurerW.TechnikderMultiorganentnahme.Viszeralchirurgie. 32. SapilakBJ.Assessmentofseverityofsymptomsofanxietyanddepression
2004;39:439–42. andqualityoflifeofpatientschronicallytreatedwithrenalreplacement
16. SollingerHW,OdoricoJS,KnechtleSJ,D’AlessandroAM,KalayogluM,Pirsch therapy.In:Applicationsofstatisticalmethodsscientificresearch,IIIStatSoft;
JD.Experiencewith500simultaneouspancreas-kidneytransplants.Ann 2008.
Surg.1998;228:284–96. 33. SmithGC,TrauerT,KerrPG,ChadbanSJ.Prospectivequality-of-life
17. DholakiaS,MittalS,QuirogaI,GilbertJ,SharplesEJ,PloegRJ,etal.Pancreas monitoringofsimultaneouspancreasandkidneytransplantrecipientsusing
transplantation:past,present,future.AmJMed.2016;129:667–73. the36-itemshortformhealthsurvey.AmJKidneyDis2010Apr;55(4):698–
18. Pérez-SáezMJ,ToledoK,NavarroMD,RedondoMD,LeónC,ArjonaA, 707.doi:https://doi.org/10.1053/j.ajkd.2009.12.025.Epub2010Feb21.
AgüeraML,Rodríguez-BenotA,AljamaP.Long-termsurvivalof PubMedPMID:20176426.
simultaneouspancreas-kidneytransplantation:influenceofearly 34. MaglakelidzeN,PantsulaiaT,TchokhonelidzeI,ManagadzeL,ChkhotuaA.
posttransplantationcomplications.TransplantProc.2011;43(6):2160–4. Assessmentofhealth-relatedqualityoflifeinrenaltransplantrecipientsand
https://doi.org/10.1016/j.transproceed.2011.05.025PubMedPMID:21839221.
dialysispatients.TransplantProc2011Jan-Feb;43(1):376–379.doi:https://doi.
19. BinautR,HazzanM,PruvotFR,DraconM,LelièvreG,NoëlC.Comparative org/10.1016/j.transproceed.2010.12.015.PubMedPMID:21335226.
studyofchronicambulatoryperitonealdialysisversushemodialysispatients 35. DrognitzO,BenzS,PfefferF,FischerC,MakowiecF,SchareckW,HoptUT.
afterkidneytransplantation:clinicalandfinancialassessment.Transplant Long-termfollow-upof78simultaneouspancreas-kidneytransplantsata
Proc.1997;29(5):2428PubMedPMID:9270795.
single-centerinstitutioninEurope.Transplantation.2004;78(12):1802–8
20. MartinsLS,MalheiroJ,PedrosoS,AlmeidaM,DiasL,HenriquesAC,SilvaD, PubMedPMID:15614154.
DavideJ,CabritaA,NoronhaIL,RodriguesA.Pancreas-kidney
transplantation:impactofdialysismodalityontheoutcome.TransplInt Publisher’s Note
2015Aug;28(8):972–979.doi:https://doi.org/10.1111/tri.12565.Epub2015
SpringerNatureremainsneutralwithregardtojurisdictionalclaimsin
Apr8.PubMedPMID:25790131.
publishedmapsandinstitutionalaffiliations.
21. KimRD,OreopoulosDG,QiuK,McGilvrayID,GreigPD,WrightE,GrantDR,
CattralMS.Impactofmodeofdialysisonintra-abdominalinfectionafter
simultaneouspancreas-kidneytransplantation.Transplantation.2005;80(3):
339–43PubMedPMID:16082329.
22. MarcacuzcoA,Jiménez-RomeroC,ManriqueA,CalvoJ,CambraF,CasoÓ,
García-SesmaÁ,NutuA,JustoI.Outcomeofpatientswithhemodialysisor
peritonealdialysisundergoingsimultaneouspancreas-kidney
transplantation.Comparativestudy.ClinTransplant2018Jun;32(6):e13268.
doi:https://doi.org/10.1111/ctr.13268.Epub2018May17.PubMedPMID:
29683218.
23. Padillo-RuizJ,Arjona-SánchezA,Muñoz-CasaresC,Ruiz-RabeloJ,Navarro
MD,RegueiroJC.Impactofperitonealdialysisversushemodialysison
incidenceofintra-abdominalinfectionaftersimultaneouspancreas-kidney
transplant.WorldJSurg2010Jul;34(7):1684–1688.doi:https://doi.org/10.
1007/s00268-010-0527-z.PubMedPMID:20300749.
24. RäihäJ,HelanteräI,EkstrandA,NordinA,SallinenV,LempinenM.Effectof
PretransplantDialysisModalityonOutcomesAfterSimultaneousPancreas-
KidneyTransplantation.AnnTransplant.2019;24:426–31.https://doi.org/10.
12659/AOT.916649PubMedPMID:31320604;PubMedCentralPMCID:
PMC6668491.
25. OjoAO,HansonJA,WolfeRA,AgodoaLY,LeaveySF,LeichtmanA,Young
EW,PortFK.Dialysismodalityandtheriskofallograftthrombosisinadult
renaltransplantrecipients.KidneyInt1999May;55(5):1952–1960.PubMed
PMID:10231459.
26. SnyderJJ,KasiskeBL,GilbertsonDT,CollinsAJ.Acomparisonoftransplant
outcomesinperitonealandhemodialysispatients.KidneyInt.2002;62(4):
1423–30PubMedPMID:12234315.
27. ZazzeroniL,PasquinelliG,NanniE,CremoniniV,RubbiI.Comparisonof
qualityoflifeinpatientsundergoinghemodialysisandperitonealDialysis:a
systematicreviewandmeta-analysis.KidneyBloodPressRes2017;42(4):717–
727.doi:https://doi.org/10.1159/000484115.Epub2017Oct19.Review.
PubMedPMID:29049991.
28. KalenderB,OzdemirAC,DervisogluE,OzdemirO.Qualityoflifeinchronic
kidneydisease:effectsoftreatmentmodality,depression,malnutritionand
inflammation.IntJClinPract.2007;61(4):569–76Epub2007Jan29.PubMed
PMID:17263698.
